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Case presentation
A 32-year-old white man developed swelling of his feet and ankles
and facial swelling in the mornings. Physical examination revealed
blood pressures ranging between 130—140/95—100 mm Hg and peripheral
edema. Laboratory evaluation showed: BUN, 9 mg/dl; plasma creati-
nine, 0.9 mg/dl; plasma total protein, 3.5 g/dl; plasma albumin, 1.7 g/dl;
and plasma cholesterol, 448 mg/dl. Urinalysis disclosed 4+ protein and
microhematuria. A 24-hour urine collection contained 17 g of protein;
creatinine clearance was 112 mllmin. Appropriate serologic tests were
negative, and a diagnosis of idiopathic nephrotic syndrome was made.
A renal biopsy yielded 14 glomeruli; one was globally sclerotic and 3
others had lesions of segmental sclerosis. Immunofluorescence and
electron microscopy established the diagnosis of focal segmental gb-
merulosclerosis.
The patient was treated with sodium restriction and diuretics for his
edema, and prednisone, 120 mg every other day, for longer than 3
months; the proteinuria did not abate. Proteinuria ranged from 11.7 to
15.8 g daily, plasma albumin from 1.9 to 1.5 g/dl, total protein from 3.6
to 4.5 g/dl, and total cholesterol from 575 to 700 mg/dl (Chem 20 panel
results). After the corticosteroids were tapered, the patient was in-
structed in a 300 mg cholesterol, low-saturated-fat diet. After 2 months
of this diet, his plasma lipids were accurately measured by ultracentrif-
ugation: cholesterol, 399 mgldl; LDL cholesterol, 329 mg/dl; VLDL
cholesterol, 33 mgldl; HDL cholesterol, 37 mg/dl; and total triglyceride,
378 mg/dl. The cholesterol-binding resin colestipol hydrochloride
(Colestid) was prescribed for 3 months; total cholesterol decreased to
341 mgldl (LDL cholesterol, 276 rng/dl; VLDL cholesterol, 32 mgldl;
HDL cholesterol, 33 mg/dl; triglyceride, 405 mg/dl). He then discontin-
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ued taking the resin binder, and the total cholesterol increased to 422
mg/dl (LDL, 301 mg/dl; VLDL, 101 mg/dl; HDL, 23 mgIdl; total
triglyceride, 574 mg/dl). Nicotinic acid, in a dose of 1500 to 2500 mg
daily, was prescribed, but the patient could not continue taking this
drug because of flushing and gastrointestinal complaints. The plasma
lipid level did not fall significantly with nicotinic acid, and treatment
with the resin binder was resumed. The patient discontinued this
medication and was followed only sporadically between 5 and 7 years
ago. During that time, nephrotic syndrome and hyperlipidemia per-
sisted. Hypertension was controlled by propranolol and hydralazine,
and he was told to eat a low-sodium, low-cholesterol, low-protein diet.
His renal function progressively deteriorated, and another renal biopsy
showed marked progression of the focal sclerosing glomerulonephritis.
Four years ago, the serum creatinine was 9 mg/dl and creatinine
clearance was less than 10 cc/mm; an arteriovenous fistula was created
in preparation for dialysis. Despile continued proteinuria of 5 to 7 g
daily, the total plasma protein had increased to 5.6 g/dl and the albumin
to 3.3 g/dl; the plasma cholesterol had decreased to 264 mg/dl. Four
years after initial presentation, at the age of 36 years, the patient
developed episodic, exertional, "burning" left chest pain, which was
associated with electrocardiographic changes suggestive of ischemia.
Cardiac catheterization revealed significant stenotic lesions of the left
anterior descending (LAD) coronary artery and of several diagonal
vessels. The major LAD lesion was successfully dilated by balloon
angioplasty; angina disappeared and a followup stress test was nega-
tive.
He started dialysis one month after the angioplasty and did well. Two
months after beginning dialysis, his fasting total triglyceride level was
281 mg/dl and total plasma cholesterol was 198 mgldl. After one year of
dialysis, he underwent a successful cadaveric renal transplant. At
discharge, plasma creatinine was 2.0 mg/dl and total cholesterol was 171
mg/dl; his immunosuppressive regimen consisted of prednisone, cycbos-
porine, and azathioprine. He had mild to moderate hypertension
controlled by hydralazine, atenolol, and verapamil; only mild protein-
uria was present. Two months after receiving the allograft, his total
cholesterol was 232 mgldl; 3 months later, while taking a maintenance
dose of 10 mg prednisone daily, his total cholesterol ranged from 267 to
280 mg/dl. (The LDL was 145 mgldl; HDL, 58 mgldl; and total
triglyceride, 250 mg/dl.) He was reinstructed in a low-cholesterol,
low-saturated-fat diet, and recently resin binders were restarted.
Discussion
DR. GERALD APPEL (Director, Clinical Nephrology, The
Presbyterian Hospital, and Professor of Clinical Medicine,
Columbia-Presbyterian Medical Center, New York, New York):
This patient's history illustrates many of the interactions be-
tween lipid metabolism and renal disease. Lipid analysis per-
formed at the onset of his nephrotic syndrome revealed marked
elevations of both total and low-density lipoprotein (LDL)
cholesterol but not of high-density lipoprotein (HDL) choles-
terol. This pattern of lipid abnormality, commonly observed in
nephrotic patients, probably placed him in a group that is at
significant risk for atherosclerotic complications. Dietary man-
agement was initiated, and lipid-lowering medications were
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Table 1. Cornmon lipid abnormalities in renal disease
Renal abnormality
Cholesterol
Total LDL VLDL HDL
Triglycerides
Nephrotic syndrome
Uremia
Hemodialysis
Peritoneal dialysis
Transplantation
ja I N-I
N-D N-D N-D
N-D N-D N-D
I I I
1b jb 1b
N
N-D
N-D
N
N-I-D"
N-I
I
I
I
1'
a N = normal, I = increased, D = decreased,b Variable percent increased; varies with time after transplantation.
subsequently administered. Despite responding to this treat-
ment, he did not continue the drug regimen, and hyperlipidemia
returned. As his renal function declined, so did his serum
cholesterol. Whether hyperlipidemia contributes to a decline in
renal function is unknown, but some evidence supports such a
hypothesis. By the time he was on dialysis, the patient's total
cholesterol had returned to normal, but he had developed
hypertriglyceridemia, common in dialysis patients. Coronary
angiography demonstrated severe atherosclerotic disease, de-
spite his being only 36 years old. Risk factors for accelerated
atherosclerosis in this patient included hypertension in addition
to the hyperlipidemia. Ultimately the patient underwent suc-
cessful renal transplantation and developed a characteristic rise
in serum cholesterol; this occurrence again posed dilemmas as
to the optimal form and goal of therapy.
The association between renal disease and hyperlipidemia
has been known for more than 100 years [1]. Only recently,
however, have we defined the patterns seen in the various
forms of renal disease, and begun to understand the significance
of the lipid abnormalities and how to treat such abnormalities
[2—51. The association between hyperlipidemia and accelerated
cardiovascular disease is now well accepted, and many recent
studies have focused on the nature and significance of lipid
abnormalities in patients with renal disease [1—5] (Table 1).
Hypercholesterolemia and lipid abnormalities are, of course, an
integral part of the nephrotic syndrome. Although hypertriglyc-
eridemia is common in patients with renal failure and in those
undergoing hemodialysis or peritoneal dialysis, the pattern of
lipid abnormalities, and the pathogenesis, in fact, differ in these
patients. I'll return to this later. Likewise, some renal transplant
patients, whether treated with azathioprine or cyclosporine, ex-
hibit abnormal lipid profiles. Recent studies have reported the
results of dietary therapy or lipid-lowering medications in these
various subsets of patients. In addition, a burgeoning literature
suggests that lipid alterations might influence the progression of
renal disease. I will review much of this literature in a few
minutes, when we look at questions that arise in hyperlipidemic
patients with renal disease. These queries include: (1) What is
the lipid abnormality, and what are the mechanisms causing it?
(2) What are the atherogenic or other risks posed by the specific
lipid abnormality? (3) How can the hyperlipidemia be treated,
and do the benefits of therapy outweigh the risks of treatment?
Physiology
The common plasma lipids are highly hydrophobic and
insoluble in aqueous solutions [2—6]. Carried in the plasma in
globular particulate form, they have a polar hydrophilic outer
surface composed in part of protein moieties. These proteins,
known as apoproteins (Apo) or apolipoproteins, are important
for activation of enzymes and for recognition of lipoproteins by
receptors. The various particles carrying cholesterol and tri-
glycerides are classified according to density, electrophoretic
mobility, and composition; these particles include: chylomi-
crons, very-low-density lipoproteins (VLDL), LDL, and HDL.
Chylomicrons, the largest and least dense particles, are formed
in the intestinal mucosa; they transport exogenous diet-derived
lipids into the lymphatics and blood and have a large content of
triglyceride. The next largest particles, the VLDL, carry most
of the circulating triglyceride in the fasting state. Low-density
lipoproteins transport most of the cholesterol in the plasma.
The densest and smallest particles, HDL, have the greatest
protein-to-lipid ratio and serve as scavengers of tissue choles-
terol.
Lipid transport occurs by two pathways, (1) an exogenous
pathway concerned with the absorption of dietary fat, its
transport by chylomicrons, and the eventual breakdown of the
derived triglyceride into glycerol and fatty acids, and (2) an
endogenous pathway. In the endogenous pathway (Fig. 1), the
liver secretes triglyceride-rich VLDL particles, the triglycer-
ides of which are cleaved into glycerol and fatty acids by the
enzyme lipoprotein lipase (LPL) located in the endothelium of
adipose and other tissues. This enzyme requires Apo CII as an
activator. The VLDL particles are reduced in size and become
remnants or intermediate-density lipoproteins (IDL). The IDL
(that is, the VLDL remnants) normally are present only tran-
siently in the plasma, and can either be taken up by the liver (via
the same receptors as LDL) or lose ApoE and be converted to
LDL particles. The LDL particles contain Apo Bl00 (which
binds to the LDL receptor) as well as a considerable amount of
cholesterol, but very little triglyceride. The LDL particles
transport cholesterol to hepatocytes and peripheral tissues and
are removed from the circulation both by the receptor-mediated
action of hepatocytes and other cholesterol-requiring tissues
and by nonspecific binding to hepatocytes and peripheral tissue.
The HDL particles, secreted by the liver and other tissues, are
transformed in the circulation from HDL3 to HDL2 particles by
the acquisition of additional protein moieties. The HDL parti-
cles readily take up free cholesterol and transport it between
cells in the body; these particles are important in the removal of
cholesterol from certain tissues. The major apoprotein associ-
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Fig. 1. Simplfied view of lipoprotein metabolism.
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ated with HDL, Apo Al is an activator of the enzyme lecithin
cholesterol acyltransferase (LCAT). This enzyme esterifies free
cholesterol in HDL, allowing HDL to transfer the cholesterol
esters to other lipoprotein particles (VLDL and LDL) for
transport to the liver and subsequent removal.
Risk of atherosclerosis
Numerous studies have confirmed the association between
elevated plasma lipids, in particular hypercholesterolemia, and
an increased risk of atherosclerotic cardiovascular complica-
tions [71. A specific fraction of the cholesterol, the HDL
component, is protective against atherosclerotic disease,
whereas other fractions (especially the LDL) are associated
with accelerated atherosclerosis [8—10]. The Framingham study
found high levels of HDL cholesterol to be strongly associated
with a low risk of atherosclerotic heart disease [11].
The relationship between hypertriglyceridemia and athero-
sclerotic heart disease is far less clear; some studies have found
it to be a risk factor in cardiovascular disease, but others have
not [12—14]. High plasma triglyceride levels might promote
atherogenesis by elevating levels of other atherogenic lipopro-
teins and by lowering levels of protective lipoproteins (HDL)
[15]. Recent studies using dietary intervention and lipid-lower-
ing agents have shown that the incidence of adverse cardiovas-
cular events can be reduced by lowering the plasma cholesterol
[16—18]. Moreover, small changes in the plasma cholesterol
appear to translate into major decreases in adverse atheroscle-
rotic complications. The Lipid Research Clinics Trial found that
lowering plasma cholesterol 1% with cholestyramine led to a
1.5% to 2.0% decrease in cardiac ischemic events [16]. Like-
wise, studies have shown that raising the HDL cholesterol has
similiar beneficial effects [17, 18]. Both the American Heart
Association and the National Heart, Lung, and Blood Institute
recommend decreasing plasma cholesterol to 200 mgldl if it
contains large amounts of LDL, and if additional risk factors for
atherosclerosis are present.
Nephrotic syndrome
Hyperlipidemia often has been considered an integral part of
the nephrotic syndrome [1, 19]. Only recently, however, have
the lipoprotein patterns been well defined and the significance
of the hyperlipidemia clarified. Moreover, there have been few
studies of the effect of treatment of the hyperlipidemia of the
nephrotic syndrome. As recently as 1981, workers reached
diametrically opposite conclusions regarding the risk of athero-
sclerotic complications in hyperlipidemic nephrotics and their
need for therapy [20, 21]. Unfortunately the data on which these
conclusions were based were limited and remain so. Few
clinical studies have assessed the incidence of coronary artery
disease in the nephrotic syndrome (Table 2) [22—28]. Most of
these studies are retrospective and flawed by small numbers,
selection bias, and lack of control for other atherosclerotic risk
factors (such as smoking, hypertension, and steroid therapy).
Some studies included patients with minimal-change disease
who would most likely not remain nephrotic and hence not
remain at risk for the long-term complications of hyperlipid-
emia. One large study involving a control group concluded that
there was no increased risk of ischemic heart disease, angina, or
other atherosclerotic complications in a group of 159 adults with
the nephrotic syndrome followed for a mean of 5 years [22]. In
Table 2. Clinical studies on cardiovascular disease in nephrotic
patients
Inclusion of
Number Duration of nephrotic syndrome Incidence of
of nephrotic with minimal- coronary
patients syndrome change pattern artery disease
15 [26} > 1 year — 33%
10 [25] > 1 year — 30%
l8[24] >lyear ? 0
31 [28] Weeks to years + 0
49[27] ? + 0
159 [221 1/3 N.S. at 4 years + Not increased
157 [23] ? + Increased
a Number in brackets refers to reference.
this study, however, many patients had minimal-change dis-
ease, and only one-third were nephrotic at 4 years. Moreover,
the major cause of mortality was "renal failure" (defined as a
plasma creatinine greater than 11 mgldl) or the need for dialysis
or transplantation. Given the high incidence of cardiovascular
disease in the population with end-stage renal disease, some of
these patients listed as "renal failure" deaths probably died
from ischemic coronary events. It is difficult in retrospective
studies to sort out the risk of atherosclerosis due to hyperlip-
idemia from that due to hypertension, steroid therapy, and renal
failure per se. Moreover, the slow rate at which atherosclerosis
and its complications develop makes it unlikely that true
prospective studies will be (lone. However, a recent study
compared 157 non-diabetic nephrotic patients with a matched
control group and found, over a 5.6 year followup, a relative
risk of coronary artery disease death of 5.5; risk of myocardial
infarction, 5.3; and of all coronary artery disease, 2.5 versus the
controls [23].
Few data are available on the pathology of the coronary
arteries in nephrotic patients. In an autopsy study reviewing the
coronary arteries of 20 such patients, significantly more athero-
sclerotic plaque and coronary luminal narrowing were found
than were encountered in non-nephrotic patients [29]. How-
ever, 17 of the 20 nephrotic patients had underlying diseases
typically associated with vascular complications; 4 had diabetes
mellitus and 13 systemic lupus erythematosus. Moreover, the
study was not controlled for steroid use, hypertension, or the
presence of renal failure. One cannot conclude from this study
that nephrotic patients without other major risk factors for
ischemic heart disease have accelerated atherosclerosis.
Recently attention has focused on the pattern of lipoprotein
abnormalities found in the nephrotic syndrome. The majority of
studies have found that total cholesterol and LDL cholesterol
(and often VLDL cholesterol) are increased in most nephrotic
patients [26-37]. As patients develop greater degrees of protein-
uria and more profound hypoalbuminemia, these lipid moieties
rise to even higher levels [30, 31]. Baxter et al also found greatly
increased levels of VLDL cholesterol with a smaller rise in the
LDL cholesterol in the most hypoalbuminemic nephrotics [31].
The data on HDL cholesterol have been less consistent, with
values ranging from high to low [1, 19, 26—38]. Again, many
studies are flawed by the inclusion of patients with diabetes,
renal insufficiency, and steroid use, and by a lack of appropriate
controls. Recent, well-controlled studies of consecutive
patients with uncomplicated nephrotic syndrome have found
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Table 3. Percentage of 100 consecutive nephrotic patients with
lipoprotein abnormalities
MC FSGS Memba DM Othera Total
N 12 18 24 20 26 100
Tot. Chol
 200 mg/dl 92 86 81 65 69 77
 240 mg/dI 92 71 71 40 54 63
> 9Oth%" 92 83 63 30 42 58
LDL Chol
> 130 mgldl 83 81 71 60 65 71
> 160 mg/dl 75 76 67 40 50 60
> 9Oth% 67 72 50 25 46 50
HDL Chol
>90% 8 11 8 5 Il 9
a MC = Minimal-change disease; FSGS = focal sclerosis; Memb =
membranous nephropathy; DM = diabetes; Other proliferative GN,
heroin nephropathy, transplant nephropathy, amyloid.b Over 90th percentile for age and sex by Lipid Research Clinics.
increased levels of total, LDL, and VLDL cholesterol but
normal levels of HDL cholesterol in the majority of subjects
[30, 381. For example, we reported 5 years ago that 14 of 20
patients each had a total plasma cholesterol greater than the
95th percentile for age and sex, and 11 of 20 had an LDL
cholesterol over the 95th percentile, but only one had an HDL
cholesterol level greater than the 95th percentile [30]. More-
over, 6 of the 20 patients had HDL cholesterol values less than
the 10th percentile when compared with age- and sex-matched
controls. The ratio of HDL cholesterol/total cholesterol was
low in 85% of patients.
Some studies have reported that patients with minimal-
change nephrotic syndrome have higher levels of HDL choles-
terol than do other nephrotic patients [39, 401. In a recent study
of 100 consecutive adult nephrotics, however, HDL levels in
patients with minimal-change disease did not differ from those
in nephrotics with other histopathologic findings [411 (Table 3).
If the risk of atherosclerosis is increased to the same extent in
hyperlipidemic nephrotics as it is in other populations with
similar degrees and patterns of hyperlipidemia, nephrotic pa-
tients also should have an increased risk of atherosclerotic
coronary vascular disease. The risk to the individual patient,
however, will depend on multiple other factors, including
genetic predisposition, the pattern and level of the elevated
lipids, the duration of unremitting nephrotic syndrome and
hyperlipidemia, concurrent hypertension, renal insufficiency,
and the use of lipid-altering medications, such as corticoste-
roids [41].
Mechanisms. The mechanisms responsible for the altered
lipoprotein metabolism in the nephrotic syndrome remain un-
clear. Many studies support a major role for increased hepatic
synthesis and secretion of lipoproteins [41]. Studies in isolated
perfused livers and in slices and homogenates of livers from
nephrotic rats show increased secretion of all lipoproteins and
also increased incorporation of amino acids and of lipid precur-
sors into lipoproteins [42—45]. Some studies also show in-
creased total hepatic cholesterol mass as well as increased
hydroxy-methylglutaryl CoA reductase activity [45, 46]. Ki-
netic studies in nephrotic humans showing an increased abso-
lute catabolic rate of LDL imply that increased synthesis
accounts for elevated serum levels [47, 48]. Turnover studies
with labeled glycerol and mevalonate have shown increased
synthesis of triglyceride and cholesterol [49]. Thus, increased
hepatic synthesis of both the lipid and protein moieties of the
lipoproteins is established.
In the nephrotic syndrome, clearance of circulating lipopro-
teins from plasma is impaired, and removal of labeled lipopro-
teins and clearance of labeled triglyceride are decreased [48,
49]. Activity of certain liporegulatory enzymes is altered, and
LPL activity is decreased 30% to 60% [41]. Likewise, LCAT is
lost in the urine of nephrotic rats [46], and plasma LCAT
activity is decreased in nephrotic humans [50]. Urinary loss of
HDL, which is only a slightly larger substance than albumin,
and of Apo Al (the major Apo in HDL) have been documented
both in nephrotic rats and humans [38, 46, 50—52]. Thus, the
abnormalities in plasma lipoproteins in the nephrotic patient
reflect the dynamic interaction of increased hepatic synthesis,
altered and diminished catabolism, and abnormal urinary losses
[1, 19, 41, 53].
Workers have attempted to identify the signal to the liver that
increases lipoprotein synthesis in the nephrotic syndrome. In
1960, Baxter and coworkers noted a close inverse relationship
between lipid levels and the plasma albumin concentration [31].
They hypothesized that the liver responds to a decrease in
serum albumin or oncotic pressure by a generalized increase in
the synthesis and secretion of plasma proteins, including the
lipoproteins [31]. Infusion of albumin or oncotic substances into
nephrotic rats and humans promptly reduced the level of
plasma lipids [54, 551. However, Yedgar et al proposed that the
liver might respond not to alterations in oncotic pressure but to
changes in plasma viscosity [56, 57]. The secretion of VLDL
triglyceride by cultured rat hepatocytes was inhibited by in-
creasing the viscosity of the bathing media, but not the mass
concentration or osmolality of the media [56]. In nephrotic rats,
increasing plasma viscosity delayed or reduced the level of
hyperlipidemia [57]. In humans with the nephrotic syndrome,
however, the plasma viscosity usually is normal or elevated;
thus, decreased plasma viscosity does not appear to be the
stimulus for increased hepatic lipogenesis [30]. Moreover, an
inverse relationship does not exist between plasma viscosity
and cholesterol, as it does between the cholesterol and both the
plasma albumin concentration and plasma oncotic pressure
[30]. It is still possible, however, that individual hepatocytes
sense a reduced "effective viscosity," because circulating
macromolecules such as lipoproteins contribute to the mea-
sured plasma viscosity in the nephrotic syndrome but are
unable to pass into the hepatic sinusoids.
Kaysen and colleagues measured the rate of albumin synthe-
sis, urinary albumin loss, and lipids in 13 nephrotic patients in
whom albumin synthesis and urinary protein excretion were
altered by changes in dietary protein content [58]. Despite an
elevated level of cholesterol and triglyceride, the rate of albu-
min synthesis in the nephrotics on a low-protein diet was similar
to control rates. Increasing the rate of albumin synthesis by
increasing the dietary protein did not change the plasma lipid
levels significantly. Thus, the serum cholesterol concentration
was completely independent of the rate of albumin synthesis
and only dependent on the rate of clearance of albumin [58].
The authors speculated that urinary loss of albumin or another
liporegulatory substance, rather than hypoalbuminemia or low
plasma oncotic pressure, stimulates hepatic lipogenesis. Yet
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Fig. 2. Proposed factors that alter plasma lipoproteins in the nephrotic
syndrome. (From Ref. 41.)
another study proposed that the lipid abnormalities in the
nephrotic syndrome are the result not of hypoalbuminemia but
of decreased renal mevalonate metabolism, which increases the
substrate available to the liver for lipogenesis [59]. Figure 2
depicts many of the factors affecting lipid levels in the nephrotic
syndrome [41].
Therapy. Several published trials have studied the treatment
of the hyperlipidemia of the nephrotic syndrome [60—70]. Early
studies with cholestyramine, nicotinic acid, and tryptophan led
to lowered levels of plasma lipids, but trials with clofibrate
produced unacceptable muscle toxicity [70]. Given the uncer-
tain risks of atherosclerosis and the limited evidence on efficacy
and safety of drug therapy, many nephrologists chose not to
treat hyperlipidemic nephrotic patients. At present, good evi-
dence indicates that specific lipoproteins raise or lower the risk
of coronary artery disease [8—11], and that lowering plasma
lipids by diet and medication in hyperlipidemic populations
without renal disease reduces the risk of adverse coronary
events. Moreover, more effective and safer new medications
are now available.
Although dietary therapy alone is often recommended as the
initial therapeutic intervention, it rarely lowers the extremely
elevated plasma lipid levels of severely nephrotic patients. A
controlled trial combining a low-cholesterol (300 mg/day) and
low-saturated-fat diet with the bile-acid-binding resin colestipol
resulted in a 20% lowering of total cholesterol and a 31%
decrease in LDL cholesterol, without producing any significant
change in the HDL cholesterol level [63]. The drug was well
tolerated, and few patients complained of gastrointestinal side
effects or unpalatable taste. A trial with the bile-acid-binding
resin cholestyramine yielded an 8% decrease in total cholesterol
and a 19% decrease in LDL cholesterol [68]. Two trials with
probucol lowered mean total cholesterol and LDL cholesterol
by almost 25% but decreased HDL cholesterol 12% to 24% [63,
66]. Probucol was generally well tolerated. This drug might
have an added beneficial effect on atherogenesis by inhibiting
oxidation of LDL, thus preventing LDL uptake by macro-
phages in the vascular wall [65]. In small numbers of patients,
short-term use of nicotinic acid produced good results in
lowering total and LDL cholesterol [63]. Gemfibrozil, a fibric
acid derivative, has been used successfully and safely to treat
11 adult nephrotic patients in a 6-week trial; the drug lowered
total cholesterol 15%, LDL cholesterol 13%, triglyceride 51%,
and increased HDL cholesterol 18% [71]. In recent short-term
studies, the hydroxy-methylglutaryl CoA reductase inhibitor
lovastatin (or a similar agent, simvastatin) has been used to
treat the hyperlipidemia of the nephrotic syndrome and has
produced a decrease in total cholesterol of 18% to 36% and a
decrease in LDL cholesterol of 18% to 47% [41, 48, 67—69]. The
HDL cholesterol was increased or unchanged in these studies
[48, 67, 68]. The decrease in the total and LDL cholesterol
clearly is directly related to the dose of lovastatin [67]. Longer
followup in small numbers of nephrotic patients has disclosed
similar results without major adverse effects [41].
In accord with our current understanding of the risk-benefit
ratio for therapy of nephrotic hyperlipidemia, I favor the
following individualized approach to treatment [41]. All ne-
phrotic patients should be instructed in a low-saturated-fat,
low-cholesterol (less than 300 mg/day) diet. This approach
might not only have beneficial effects on atherogenesis, but also
could prevent lipid-induced glomerular damage. I'll return to
this point later. Other atherosclerotic risk factors such as
smoking, hypertension, and medications that elevate plasma
lipids should be eliminated. Patients with unremitting nephrotic
syndrome and with significantly elevated levels of lipoproteins
and unfavorable lipoprotein patterns, as well as hypercholes-
terolemic patients with preexisting vascular disease or other
risk factors for atherosclerotic disease (hypertension, male
gender, smoking, etc.), are most likely to benefit from drug
treatment. Although the antihyperlipidemic agent of choice is
not yet known, the lipoprotein pattern of the patient during
therapy should be monitored to ensure lowering of total cho-
lesterol and LDL cholesterol without lowering HDL cholesterol
levels.
Uremic and dialyzed patients
Considerable evidence indicates that patients undergoing
chronic dialysis have a high incidence of coronary artery
disease and accelerated atherosclerosis [72—75]. Lindner and
colleagues observed a 56% mortality rate at the end of 13 years
of followup of long-term hemodialysis patients; more than
one-half of the deaths were attributed to arteriosclerotic com-
plications [72]. Ritz et al noted the relative risk of fatal
myocardial infarction to be 9- to 170-fold greater in dialyzed
patients than in the general population [76]. Samples from the
renal and internal iliac arteries of uremic patients also have
shown accelerated atherosclerotic and vascular aging changes
as compared with vessels from control populations [77, 78].
Cardiovascular deaths remain a leading cause of mortality in
dialysis patients [79]. Considerable debate remains as to
whether the high risk of cardiovascular morbidity is related to
the dialytic process, but researchers agree that many patients
enter dialysis with accelerated atherosclerosis, which can lead
to a high risk of early mortality during the first years of dialysis
[73, 76].
Although many factors undoubtedly contribute to the accel-
erated atherosclerosis, lipid abnormalities have been suggested
as a major cause, and hyperlipidemia has correlated with
increased cardiovascular mortality in some studies [76, 79—81].
A number of recent reviews have focused on the subject of
renal failure, dialysis, and lipid abnormalities [2—5, 82].
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Lipid patterns. Aside from patients with an associated state
producing lipid abnormalities (such as the nephrotic syndrome),
the cause of the renal failure does not seem to influence the
pattern of lipid abnormality. Hypertriglyceridemia is the most
common abnormality in patients with renal failure. Most large
studies have found elevated triglyceride in 50% to 75% of all
dialyzed patients [3, 74, 75, 81, 83—90]. In one study, the
hypertriglyceridemia initially appeared in some patients when
the glomerular filtration rate was as high as 50 mI/mm, and the
prevalence of hypertriglyceridemia increased as the GFR of the
studied population declined [89]. Hypertriglyceridemia occurs
in undialyzed patients with renal failure, those on hemodialysis,
and those on peritoneal dialysis; typically it is associated with
increased levels of VLDL and the type-IV Fredrickson pattern
of hyperlipidemia. Norbeck and coworkers reported an altered
composition of the various lipoprotein fractions, with increased
triglyceride in VLDL and IDL, and decreased cholesterol in
HDL [91]. Abnormal accumulation of remnants of triglyceride-
rich lipoproteins, probably IDL, in dialysis patients has been
proposed as an explanation for the presence of certain apopro-
teins not usually found in the serum [86, 90].
Hypercholesterolemia rarely occurs in uremic and dialyzed
patients, and a number of studies have found low total choles-
terol levels in this population [74, 82, 90, 92]. The HDL
cholesterol values have been reported to be low in 50% to 75%
of undialyzed uremic and hemodialyzed patients [81, 82, 90,
93]; these patients also have a low HDL cholesteroL/LDL
cholesterol or HDL cholesterol/total cholesterol ratio [3, 75, 85,
86]. Ponticelli et al found no correlation in dialysis patients
between plasma triglyceride levels and age, gender, dialysis
duration, basal glucose level, or insulin response to intravenous
glucose [74]. One large study did identify major differences in
the lipoprotein patterns of dialyzed patients of different races
[94]. White males had higher levels of triglyceride, and lower
levels of HDL cholesterol, Apo A!, and Apo All than did black
males. White males also had lower HDL2 levels than did black
males; the HDL2 levels correlated with a higher incidence of
cardiovascular mortality in the white population. Another large
study found that coronary heart disease was significantly more
common in groups with high VLDL and low HDL cholesterol
[81]. When followed sequentially over time, total and JIDL
cholesterol levels both decline in hemodialysis patients [821.
The lipoprotein abnormalities and the mechanism(s) causing
them appear to differ between CAPD and hemodialysis pa-
tients. Most patients enter CAPD with lipoprotein abnormali-
ties similar to those of the rest of the uremic population.
Hypertriglyceridemia, if not already present, develops in most
such patients within 2 to 3 months after they begin CAPD [95,
96]. In addition, levels of VLDL, LDL, and total cholesterol as
well as VLDL triglyceride all rise during the first months of
CAPD [95, 961. One study that did not show a change in total
cholesterol after 9 to 10 months of CAPD had baseline values
that were higher when CAPD was begun [82]. The level of HDL
cholesterol has varied among several studies, but it does not
increase with time on CAPD [82, 95—97]. In one interesting
study, Breckinridge and colleagues divided a group of CAPD
patients into three subgroups. The normolipidemic, nondiabetic
CAPD patients showed an increase in HDL cholesterol to
normal values during 3 to 6 months of CAPD; the patients who
were hypertriglyceridemic or who had diabetes at the onset of
CAPD showed no increase in HDL cholesterol over time on
CAPD [98]. Two studies were able to correlate the hyperlipid-
emia with the amount of glucose absorption from the perito-
neum during CAPD (100—200 g/24 hours) [95, 96].
Dialysate drained from CAPD patients contains both low-
and high-density lipoproteins. Although Al, All, CII, CIII, and
B all have been detected in the dialysate, Breckinridge et al
believe that removing these lipoproteins from the dialysate
produces only a small change in plasma lipoprotein levels [98].
Other researchers have found greater loss of the Apo Al and
All (associated with HDL) than of Apo B (associated with
LDL) and concluded that these losses might be significantly
large to influence serum levels and alter the atherogenic risk
profile of CAPD patients [82, 97].
Mechanisms of hyperlipidemia. Most evidence supports de-
creased triglyceride and VLDL removal as the cause of the
hypertriglyceridemia found in patients with renal failure. Thus,
studies found impaired clearance of exogenously administered
chylomicrons and delayed disappearance of radiolabeled tri-
glyceride in experimental animals, as well as delayed triglycer-
ide turnover in patients with renal failure both before and during
treatment with either hemo- or peritoneal dialysis [83, 99]. The
impairment in peripheral catabolism of VLDL and removal of
triglyceride is secondary to impaired hepatic triglyceride lipase
activity and lipoprotein lipase activity [3, 86, 99]. Triglyceride
in VLDL and chylomicrons are normally hydrolyzed by LPL.
Post-heparin lipolytic activity, an indirect measure of LPL, is
decreased in uremic patients and in those on dialysis [85, 861.
Such decreased post-heparin lipolytic activity in turn might be
due to low levels of Apo CII, a cofactor necessary for LPL
activation. In one large study of lipid abnormalities in dialysis
patients, LPL activity correlated inversely with serum triglyc-
eride levels and directly with HDL cholesterol levels [86]. In
hypertriglyceridemic patients on hemodialysis who were
treated with the lipid-lowering drug clofibrate, plasma triglyc-
eride and VLDL triglyceride decreased, but HDL cholesterol
increased; these changes occurred in association with increases
in adipose tissue LPL and post-heparin LPL [100]. The absence
of a change in hepatic lipase activity suggested a major role for
impaired LPL activity in the hypertriglyceridemia of renal
failure [100]. Drawing on experimental studies in dogs with
chronic renal failure, Akmal et al recently have suggested that
excess parathyroid hormone decreases LPL activity and thus
causes impaired triglyceride removal from the circulation as
well as hyperlipidemia [101]. There is also evidence for under-
utilization of lipoproteins in a rat model of renal insufficiency; it
is unclear whether this model is relevant, because uremic rats
have significant elevations of all plasma lipids (cholesterol as
well as triglyceride) [1021.
Some evidence also suggests increased production of triglyc-
eride. Increased production could result from stimulation of
hepatic VLDL synthesis by the provision, via the dialysate, of
precursors of fatty acid synthesis (for example, acetate) or
through impaired carbohydrate tolerance. An additional mech-
anism for abnormal lipid profiles in uremic individuals is low-
ered LCAT activity. Normally, increased levels of VLDL and
triglyceride stimulate LCAT activity. But this does not appear
to be the case in uremia; hence the VLDL might fail to promote
its own clearance in uremia [92]. Dieplinger et al noted low
levels of both cholesterol esterification and cholesterol ester
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transfer rates to VLDL and LDL in patients with end-stage
renal disease who are treated with hemodialysis, as compared
with controls [103]. The LDL triglyceride content was mark-
edly increased, as contrasted with that of a CAPD group with
normal values.
Treatment. Studies have documented the efficacy of low-
cholesterol, low-saturated-fat isocaloric diets in patients with
renal failure, even in those treated with hemodialysis [104—1081.
Typically, levels of triglyceride, VLDL, and LDL cholesterol
decrease, and HDL and HDL cholesterolltotal cholesterol
ratios increase. The cost of such diets, their acceptability, and
their long-term benefits remain to be defined.
Only limited studies are available on the effect of drug
therapy in controlling the hyperlipidemia of renal failure. Clofi-
brate can cause myositis in patients with renal failure and
should not be used in regular doses [1091. Several studies in a
limited number of hemodialysis patients using low doses of
clofibrate (1—2 glweek) have shown a significant decrease in
plasma triglyceride and an increase in HDL cholesterol without
evidence of significant muscle damage [100, 1101. Using a
dietary supplement of fish oil capsules rich in eicosapentanoeic
acid, Hamazaki et al achieved a significant decrease in plasma
levels of triglyceride and total cholesterol in 12 hyperlipidemic
dialysis patients [1111. However, in five-sixths nephrectomized
rats fed fish oil instead of beef tallow, renal function declined
faster and glomerulosclerosis progressed more rapidly [1121.
Oral charcoal administered to 6 patients with renal insufficiency
significantly reduced serum cholesterol and triglyceride in the
three most hyperlipidemic patients [113]. Carnitine supplemen-
tation, postulated to stimulate long-chain fatty acid oxidation,
and thereby decrease substrate availability for triglyceride
synthesis, has resulted in extremely variable responses of the
hyperlipidemia in dialysis patients [114]. A recent trial of the
hydroxy-methylglutaryl-CoA reductase inhibitor lovastatin in
18 hyperlipidemic hemodialysis patients reduced mean total
cholesterol from 280 to 213 mgldl and LDL cholesterol from 161
to 112 mgldl without altering HDL cholesterol levels [115].
Triglyceride values were only minimally changed in this study
[1151.
Premature cardiovascular morbidity might relate to elevated
VLDL levels, decreased HDL concentration, or abnormalities
of composition of the various lipoproteins in patients with renal
failure. In some studies, dialysis patients with cardiovascular
disease have had a higher mean triglyceride level than did
patients without cardiovascular events. Other studies failed to
relate cardiovascular events to hyperlipidemia, however [73,
74]. It is unclear whether some studies had too short a followup
period to detect major cardiovascular events, or whether they
did not relate crucial lipid factors (such as HDL cholesterol) to
the risk of arteriosclerotic complications. In one large study of
almost 350 nondiabetic patients on chronic hemodialysis, white
males had the highest rate of cardiovascular mortality and
highest levels of plasma triglyceride, as well as the lowest levels
of HDL cholesterol [94]. Therapy such as dietary restriction,
exercise programs, avoidance of lipid-elevating medications,
and correction of other risk factors for cardiovascular disease
(such as smoking) all seem logical. More drastic measures such
as the use of lipid-lowering drugs or changes in peritoneal
dialysis regimens (such as avoiding high dextrose concentra-
tions or using osmotic agents other than glucose) are probably
best reserved for patients at highest risk for cardiovascular
complications.
Lipid abnormalities after renal transplantation
Lipid patterns. Complications of accelerated atherosclerosis
are a major cause of morbidity and mortality in renal transplant
recipients [116—119], and the subset of hyperlipidemic patients
seems to be at increased risk for these sequelae. Cardiovascular
disease is responsible for approximately 40% of deaths after
transplantation [116]. Whereas hypertension and the presence
of accelerated atherosclerosis consequent to the preceding
dialysis undoubtedly contribute to the development of cardio-
vascular disease, the lipid abnormalities specific to transplant
patients are thought by some to be a major factor in the
morbidity of this group. In a study of more than 200 transplant
recipients, 7% had had a myocardial infarction [118]. The
patients who had had infarcts also had significantly higher total
cholesterol levels than did the rest of this transplant population
[118]. In another, more recent study of more than 500 transplant
patients, cardiovascular and cerebrovascular occlusive epi-
sodes occurred in almost 10% [120]. Again, these events were
significantly more common in the hyperlipidemic patients.
Unfortunately, early retrospective studies did not clearly
define the nature of the lipid abnormalities, the associated
factors, and the potential mechanisms of the hyperlipidemia.
Such studies often focused on a limited cross-section of the
transplant population, with patients receiving variable immuno-
suppressive regimens at variable time intervals following trans-
plantation, and with the variable presence of complicating
features (for example, diabetes, heavy proteinuria, lipid-alter-
ing antihypertensive therapy). Recent studies have overcome
many of these problems by following large numbers of patients
sequentially [118, 120]. Nevertheless, there are few studies of
the effect of lipid-lowering therapy on the lipid abnormalities
occurring after transplantation.
Numerous studies have documented hyperlipidemia in some
renal transplant patients receiving azathioprine and prednisone
as their main immunosuppressive regimen. As early as 1973,
Ghosh et al reported a significant elevation of both plasma
cholesterol and triglyceride in a group of 32 renal transplant
recipients [121]. Subsequent studies have confirmed hyperlip-
idemia in a significant portion of the transplant population [74,
75, 117, 118, 120—125]. The incidence of hypercholesterolemia
ranges from 16% to 78%, and the incidence of hypertriglycer-
idemia from 9% to 66% in transplant recipients receiving
prednisone and azathioprine [118, 119, 122—125]. The wide
variation in the incidence of lipid abnormalities largely reflects
the different populations. In patients followed sequentially, the
onset of the hypercholesterolemia typically occurs within 3
months after transplantation, and, by 6 months, 70% of patients
who are going to manifest hypercholesterolemia have done so
[120, 121]. Plasma cholesterol levels peak at 4 to 10 months post
transplant and tend to decline from 12 to 36 months afterward.
Plasma triglyceride values typically fall during the first month
after transplantation, rise progressively (peaking at 4 to 12
months post transplantation), and then gradually decline [119—
121, 123]. In one study of more than 200 transplant recipients
with well-functioning allografts, 27% of the patients were hy-
percholesterolemic at one year, and 23% were hypertriglycer-
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idemic [1181. At last followup in that study (mean of 5 years),
30% were hypercholesterolemic and 29% hypertriglyceridemic.
Studies of the pattern of lipid abnormalities in transplant
recipients have found elevated levels of total, LDL, and VLDL
cholesterol [85, 88, 121, 125]. Values for HDL cholesterol
usually have been high or normal, with occasional reports of
low values [85, 88, 119, 124]. In a study examining the sub-
classes of HDL in renal transplant recipients, total HDL and
HDL2 were normal, and HDL3 was reduced, as in hemodialy-
sis patients [126]. In one study of patients followed sequen-
tially, HDL cholesterol was 52 mg!dl at one year post-transplant
and increased to 64 mg/dl at last followup; the ratio of total!
HDL cholesterol declined from 5.08 to 4.36 [1181. The LDL
cholesterol did not change significantly during this period. The
composition of lipoproteins also is abnormal in renal transplant
recipients; HDL is enriched with triglyceride and Apo A [127,
128].
Recent investigations have examined the lipid patterns and
abnormalities in patients treated with cyclosporine [120, 129].
In a short-term study of 43 patients, Markell et al showed an
increase in mean total serum cholesterol, to 253 mg!dl at 3
months from a pretransplant level of 192 mgldl, and an increase
in serum triglyceride, from a pretransplant level of 203 mg!dl to
a 3-month value of 231 mgldl [129]. In a study of almost 500
transplant patients treated with cysclosporine and prednisone,
38% were severely hypercholesterolemic (total cholesterol >
300 mg/dl), and most patients developed the hypercholesterol-
emia within 6 months of transplantation [120]. Only 15% and
13% of patients remained hypercholesterolemic at 2 and 3 years
post transplant respectively. Severe hypertriglyceridemia (tri-
glyceride> 500 mg!dl) occurred in 15% of the patients, with the
peak incidence at 12 months post transplant. Only 7% of the
patients remained hypertriglyceridemic at 2 and 3 years. There
was no difference in the incidence and severity of hypercholes-
terolemia between patients treated with cyclosporine and pred-
nisone and those treated with azathioprine and prednisone, but
the azathioprine group did have more severe hypertriglycerid-
emia. These findings contrast with those of other studies that
found a significant decrease in serum cholesterol and triglycer-
ide after patients were converted from a regimen of cyclospo-
rine-prednisone to one of azathioprine-prednisone [130]. Some
studies also found a higher mean cholesterol value in patients
treated with cyclosporine or with cyclosporine plus steroids in
comparison with those treated with azathioprine plus steroids
[129, 130, 131]. Lipoprotein analysis showed that LDL choles-
terol values were significantly elevated, whereas HDL choles-
terol values were normal or elevated [120, 130, 131]. In the few
studies of patients treated with cyclosporine alone, the inci-
dence of hypercholesterolemia has been reportedly lower than,
or the same as, that in transplant patients treated with cyclo-
sporine coupled with steroids [120, 131].
Mechanisms. The cause of the hyperlipidemia in renal trans-
plant patients is multifactorial [132]. Factors reported to posi-
tively correlate with post-transplant hyperlipidemia include: (1)
daily or total prednisone dose, (2) the use of cyclosporine, (3)
relative body weight or obesity, (4) renal dysfunction, (5) blood
glucose concentration, (6) proteinuria, (7) patient age and
gender, (8) the presence of diabetes, and (9) the use of certain
diuretics or beta-blocking drugs. Some of these factors strongly
correlate with both hypercholesterolemia and hypertriglycerid-
emia, whereas others correlate with the level of only one lipid
type in limited populations.
Of all the relationships reported, the most compelling evi-
dence is for a positive correlation between the daily or total
cumulative dose of corticosteroids and hyperlipidemia. This
correlation holds for both hypercholesterolemia and hypertri-
glyceridemia. In a few studies, the use of corticosteroids was
believed to be the single most important factor in the pathogen-
esis of post-transplant hyperlipidemia [120, 126]. Abnormal
lipid values decline with time after transplantation as the steroid
dose is decreased [120]. In one study, hypercholesterolemia
decreased in transplant patients after daily corticosteroid dos-
age was changed to an alternate-day regimen [133]. Other
investigators have not found this to be true [123, 134]. Like-
wise, the withdrawal of corticosteroids from cyclosporine-
prednisone treated patients has led to a dramatic and sustained
decline in hypercholesterolemia; this finding correlates with
animal data showing that corticosteroids can induce hypercho-
lesterolemia, increase hepatic lipoprotein and triglyceride pro-
duction, and impair triglyceride removal [119, 120]. In non-
transplant populations receiving long-term corticosteroids,
hypercholesterolemia and hypertriglyceridemia also have been
noted [122].
Ibels and colleagues documented impaired triglyceride clear-
ance due to reduced post-heparin plasma lipolytic activity in
patients with abnormal graft function [134]. Other workers,
although confirming impaired VLDL triglyceride removal,
could not attribute this change to changes in post-heparin LPL
activity [5, 99, 135]. Investigators have proposed increased
hepatic triglyceride synthesis [5, 1241. Cattran et al studied 25
patients 18 to 36 months following transplantation and noted
hypertriglyceridemia in 44% [124]. Turnover studies docu-
mented overproduction of triglyceride as the major hyperlipid-
emic effect [124]. This defect was partially ameliorated by
changing patients to alternate-day steroid therapy. The corre-
lation noted by this group and others between basal insulin
levels and serum triglyceride concentrations suggested that
glucocorticoid-stimulated hyperinsulinism might stimulate he-
patic triglyceride production. Although other studies have
confirmed the relationship between increased triglyceride levels
and prednisone dosage [118, 123, 125], not all researchers have
found elevated basal insulin levels [75]. Moreover, some recent
studies have failed to document any positive independent
relationship between steroid dosage and triglyceride levels,
despite the positive correlation with cholesterol levels [118].
Finally, at least one large study confirmed a relationship be-
tween hypercholesterolemia and steroid dosage at only one
year post transplant and not at long-term followup (mean of 5
years post transplant) [118]. This finding suggested to the
authors that the major lipemic effect of corticosteroids occurs
early in the posttransplant period.
Several groups have documented a decrease in the levels of
triglyceride and cholesterol following conversion from cyclo-
sporine to azathioprine therapy; this decrease suggests that
cyclosporine itself is a factor in the production of posttransplant
hyperlipidemia [131, 132, 136]. Markell and Friedman noted a
higher total cholesterol level in cyclosporine-prednisone-
treated cardiac transplant patients than in azathioprine-pred-
nisone-treated patients [117]. Several other studies, however,
have not been able to document a correlation between cyclo-
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sporine dose and concentrations and serum cholesterol or
triglyceride levels [117, 125]. Moreover, a recent well-designed
study of more than 500 transplant patients documented a
negative correlation between cyclosporine dose and both serum
triglyceride and cholesterol levels [120]. The mean dosage of
cyclosporine was lower in hyperlipidemic transplant patients
than in those without severe hyperlipidemia. Likewise, the
serum cholesterol level fell with corticosteroid withdrawal in a
small group of patients maintained on cyclosporine immuno-
suppression alone.
Several studies have documented a positive correlation be-
tween relative body weight or obesity and posttransplant hy-
pertriglyceridemia and hypercholesterolemia [118—120, 1251.
Others have been unable to relate either diet or excessive
weight gain to the hyperlipidemia [123, 124, 1291. Reduced renal
function correlates positively with hypertriglyceridemia and/or
hypercholesterolemia in most studies [88, 118—120, 1251. It
remains unclear whether the effect actually is related to the
effects of higher corticosteroid dosages or to the use of cyclo-
sporine.
Other factors associated with post-transplant hyperlipidemia
include increased age of the patient, female gender, and the
presence of diabetes mellitus [118, 120, 124, 125, 137]. Trans-
plant patients with nephrotic-range proteinuria are often hyper-
lipidemic [118, 1201. As I noted earlier, some of the medications
used to treat fluid retention or hypertension—such as loop
diuretics, thiazides, and beta blockers—have been associated
with increased levels of triglyceride or cholesterol. Finally,
elevated pre-transplant total, LDL, and VLDL cholesterol
levels have been suggested in one study as the most important
factor in predicting which patients will be hypercholesterolemic
after transplantation [1181.
A number of studies have focused on treatment of post-
transplant hyperlipidemia. Dietary therapy has proven success-
ful in some studies [122, 137, 1381. Some workers have found
that changing to alternate-day steroid treatment is successful in
lowering lipid levels [121, 124, 133]; others have not had
success with this maneuver [119, 122, 139]. Likewise, conver-
sion from cyclosporine to azathioprine therapy has had mixed
results [129, 136]. Therapy with lovastatin has lowered lipids
successfully in azathioprine-treated transplant patients [129].
However, when this medication was used in cyclosporine-
treated cardiac transplant recipients, it was associated with
rhabdomyolysis and acute renal failure [140, 141]. Neverthe-
less, lovastatin appears to be efficacious and safe in cyclospo-
rime-treated renal transplant recipients when used in low doses
and monitored closely [142, 143].
Hyperlipidemia and the progression of renal disease
Evidence indicates that lipids might play a causative role in
progressive glomerular damage [144, 145]. Studies in animals
fed lipogenic diets, in animal models of endogenous hyperlip-
idemia, and in hyperlipidemic animals treated with lipid-lower-
ing drugs all support the adverse effect of hyperlipidemia on the
progression of glomerulosclerosis [144, 146, 147]. Recent stud-
ies have suggested a number of possible mechanisms of this
adverse effect.
In several animal species, including the rat, guinea pig, and
rabbit, lipogenic diets lead to focal glomerulosclerosis. The
extent of glomerular injury often correlates with the serum
cholesterol. In some models, glomerular enlargement, mesan-
gial expansion, and hypercellularity precede focal glomerulo-
sclerosis [144, 146, 147]. Endogenous hyperlipidemia in genet-
ically obese Zucker rats also is associated with progressive
glomerulosclerosis and alburninuria [148]. Progressive eleva-
tions of serum cholesterol levels in these animals correlate with
the development of albuminuria and glomerular damage [147].
In obese Zucker rats, treatment with either lovastatin or
clofibric acid (two unrelated lipid-lowering agents) decreased
albuminuria and glomerulosclerosis [1481. Glomerular hemody-
namics were no different than those in controls not treated with
the lipid-lowering drugs. In uninephrectomized animals with
puromycin-aminonucleoside-induced nephrotic syndrome, re-
duction of secondary hypercholesterolemia by lovastatin re-
duces the extent of glomerular injury [149]. Similar favorable
results have been obtained by lowering the lipid levels of rats
with five-sixths nephrectomy. Animals treated with the lipid-
lowering medications lovastatin or clofibric acid had less albu-
minuria and less progressive glomerulosclerosis than did con-
trol animals [150]. No changes in systemic blood pressure or
glomerular capillary pressure were noted. Protection from
glomerular injury seemed to be more a function of lowering the
serum cholesterol rather than of lowering the serum triglycer-
ide, because clofibric acid, which affected only the cholesterol
level, had a salutary effect equal to that of lovastatin, which
lowered both the cholesterol and triglyceride levels. Likewise,
in the Dahl salt-sensitive, hypertensive rat, lowering cholesterol
with lovastatin reduced albuininuria and focal segmental gb-
merulosclerosis [147]. Thus, in many forms of glomerular
damage, lowering serum lipids and cholesterol is associated
with a reduction of structural and functional renal damage.
There has been much speculation about the mechanisms by
which hyperlipidemia might accelerate glomerular damage (Fig.
3) [144—146]. Mesangial cells resemble modified smooth muscle
cells and can accumulate lipid material; they show specific
binding and uptake of LDL [144, 146, 151] and proliferate in
response to LDL. Most recently, mesangial cells have been
shown to have receptors for oxidized LDL, and oxidized LDL
uptake has been documented in vitro and in vivo by glomeruli.
This oxidized, more toxic form of LDL is thought to be
involved in the production of atherosclerosis [152—154]. Intra-
glomerular lipid deposition also is seen in experimental focal
glomerulosclerosis [155]. Recently, an increased content of
cortical cholesteryl esters and abnormal phospholipid-fatty acid
accumulation was closely linked to both glomerular and tubu-
lointerstitial disease in an animal model of progressive renal
damage [156, 157]. Moreover, cholesterol-fed animals also have
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Fig. 3. Potential mechanisms of lipid-induced renal damage.
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become hypercholesterolemic and develop glomeruloscierosis
and tubulointerstitial disease in association with increased renal
cortical cholesteryl ester accumulation [157, 158]. Micropunc-
ture studies in this model demonstrate increased glomerular
capillary pressure [157]. Infiltrating monocytes have been dem-
onstrated in some of these models and might have a pathoge-
netic role in the production of glomerutosclerosis [157, 158].
Some investigators have proposed that it is the combination of
hypercholesterolemia and intraglomerular hypertension that
leads to progressive glomerular damage [159]. Also, LDL
cholesterol can cause monocyte adherence to vascular endo-
thelial cells, and this adherence can occur in the glomerulus.
Foam cells found in the glomeruli in certain diseases can result
from the uptake of modified LDL by monocytes/macrophages
or mesangial cells. Elevated levels of LDL cholesterol also can
cause vascular endothelial damage.
Although in-vitro evidence suggests many of these potential
mechanisms, no conclusive evidence has verified that hyperlip-
idemia causes or accelerates focal glomerulosclerosis in hu-
mans [144, 145, 157]. In a small number of morbidly obese
nephrotic patients with focal glomerulosclerosis, dietary reduc-
tion leading to weight loss was associated with remission of the
nephrotic syndrome and a dramatic reduction of proteinuria
[160]. Although such results generally were associated with
declines in the serum cholesterol level, the initial serum cho-
lesterol value was not elevated in one such patient, and it
remained elevated in another despite major reductions in pro-
teinuria. A small number of other patients with genetic defects
of lipid metabolism [161, 162] or various other glomerular
diseases [163] have been shown to have evidence of large
amounts of glomerular lipid deposition. Thus, despite great
interest and considerable research, the role of lipids in produc-
ing progressive glomerular damage in humans remains to be
clarified.
In summary, lipoprotein abnormalities are common in many
forms of renal disease. The exact role of hyperlipidemia in the
cardiovascular morbidity and mortality in patients with these
renal diseases or in the progression of glomerular damage
remains to be defined. Nevertheless, a better understanding of
the patterns of hyperlipidemia, the mechanisms leading to
them, and the potential risks of these lipid abnormalities has
evolved in recent years. In the individual patient, the potential
benefits of treatment with dietary intervention or drug therapy
still must be weighed against the potential drawbacks of ther-
apy.
Questions and answers
DR. ERNST SCHAEFER (Director, Lipid Clinic, New England
Medical Center; and Chief, Lipid Metabolism Laboratory,
USDA Human Nutrition Research Center on Aging at Tufts
University, Boston, Massachusetts): I'd like to congratulate
you on an excellent overview. I have one comment and two
questions. In patients with nephrotic syndrome, albumin infu-
sion can transiently correct hypercholesterolemia [54]. This
finding is consistent with your concept about oncotic pressure
and albumin, and would undermine the concept that urinary
loss of a regulatory substance causes hyperlipidemia. A high-
molecular-weight species (3 x 106 million), LDL contributes to
the oncotic pressure of plasma. Have you run into any problems
with giving lovastatin to patients who are nephrotic, and what
about patients who have borderline renal insufficiency?
DR. APPEL: Certainly the albumin infusion data, which are
old and harken back to Baxter and Goodman's work in the early
l960s, are very persuasive. In terms of using lovastatin, it has
now been used in many nephrotic patients, and it has been
extremely well tolerated. Our own patients have had no trouble
with liver abnormalities, gastrointestinal side effects, or rhab-
domyolysis.
DR. SCHAEFER: Have those nephrotic patients had mildly
elevated creatinine levels?
DR. APPEL: Some of them have a serum creatinine in the 2-4
mg/dl range, but we have not treated nephrotic patients who
have more severe renal insufficiency. I do not know whether
lovastatin is safe and effective for patients whose serum creat-
mine is greater than 4 mg/dl.
DR. SCHAEFER: My last question relates to hemodialysis
patients with chronic renal failure who have established ather-
osclerosis, normal LDL cholesterol levels, hypertriglycerid-
emia, and low HDL cholesterol values. What do you do with
those patients? I take it from your presentation that you would
not recommend any form of medication.
DR. APPEL: That's a good and difficult question. I recently
was at a symposium attended by many lipid experts and
nephrologists with considerable expertise in dialysis [164]. No
consensus emerged as to how to treat this population. It was
clear that the majority of nephrologists and lipid experts were
offering no treatment other than dietary therapy. I'd even be
reluctant to use dietary therapy in some dialysis patients who
are less than optimally nourished. In general, yes, I think
everybody should be on a low-saturated-fat diet and eat less
than 300 mg of cholesterol. But when you impose more rigid
diets, with only 150 mg of cholsterol daily and less than 20% fat
of the total in a population in which you're already restricting
other things as well, I think that's difficult for the patient.
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston): In terms of the mech-
anism of the altered lipoprotein pattern in the nephrotic syn-
drome, are other hypoalbuminemic states associated with sim-
ilar lipid abnormalities?
DR. APPEL: It's very difficult to find other hypoalbuminemic
states that correlate well with this. Analbuminemic people have
been studied, but they have other plasma proteins and usually
aren't protein depleted. Further, peritoneal dialysis patients can
lose large amounts of albumin in the dialysate but, as I've
discussed, their situation is complicated. Many other hypoal-
buminemic states such as starvation are associated with low
plasma lipid levels.
DR. MICHAEL P. MADAIO (Division of Nephrology, New
England Medical Center): Could you be more specific about the
approach to therapy of hyperlipidemia in patients with kidney
transplants? More specifically, when do you initiate therapy?
Are there absolute or relative contraindications to any therapy?
What are your end points?
DR. APPEL: First, in terms of initiating therapy, it appears
that the percentage of patients who are hypercholesterolemic
decreases with time alter transplantation. It seems prudent to
delay therapy other than dietary intervention in transplant
patients during the early posttransplant period, when they are
receiving higher doses of corticosteroids and are likely to be
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treated for rejection episodes. Thus, approximately 6 months
after transplantation is when we should direct vigorous therapy
towards control of hyperlipidemia. Patients who are hypercho-
lesterolemic and who have a high LDL cholesterol will proba-
bly benefit most from antihyperlipidemic drug therapy. We
have used the HMG CoA reductase inhibitor lovastatin in
patients who are receiving azathioprine and corticosteroids for
immunosuppression. We have not used this drug in the group
treated with cyclosporine and prednisone maintenance basi-
cally because we fear the occurrence of rhabdomyolysis, which
has been seen in the cardiac transplant population. However, at
least three centers have reported that low-dose lovastatin (20
mg/day) is well tolerated in the cyclosporine-treated renal
transplant population. So perhaps this is the way to the future.
We've had some vigorous debates about whether to treat our
patients on cyclosporine therapy who are still hyperlipidemic
after dietary therapy with lovastatin or other lipid-lowering
agents. Lovastatin is certainly more effective than any of the
other lipid-lowering agents in terms of reducing LDL and total
cholesterol.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): At the British
Renal Association meeting in Glasgow in 1989, the higher
annual death rate in U.S. dialysis patients than in European
dialysis patients, approximately 23% versus 10% to 12% per
year, was discussed. Could you speculate on how much of this
difference might be related to differences in hypercholesterol-
emia and cardiovascular disease?
DR. APPEL: Those are interesting figures. I do not know how
significant is the role of hyperlipidemia in such mortality
statistics. It would be interesting to look at whether the dietary
differences correlate from country to country with mortality.
DR. ANDREW S. LEVEY (Division of Nephrology, New En-
gland Medical Center): I want to follow up on Dr. Schaefer and
Dr. Harrington's point that the prevalence of coronary artery
disease and other clinical expressions of atherosclerosis in
patients on hemodialysis is high, yet the elevations in choles-
terol are really not so striking. How closely is the lipid abnor-
mality related to atherosclerosis in this population? Also, would
you consider it worthwhile to carry out a clinical trial of
triglyceride-reducing diets and agents to reduce the incidence of
atherosclerosis-related clinical events?
DR. APPEL: When I spoke about the atherosclerotic risk in
uremic and dialyzed patients, I presented the supporting data,
but I also said that contrasting studies have shown that the
vascular changes seen at pathologic examination may be due to
hypertension and calciumlphosphorus abnormalities. There is
also controversy regarding the mortality rates of this popula-
tion. Some studies could not find an increase in the mortality
rate attributed to atherosclerosis in the study populations when
they controlled smoking, hypertension, and other factors such
as age, male gender, etc. The significance of the risk of the lipid
abnormalities in patients on hemodialysis has been soundly
debated. One of the confounding variables that one cannot
easily sort out is the background these patients bring to dialysis,
including metabolic problems related to renal failure, hyperten-
sion, and hyperlipidemia from the nephrotic syndrome. That's
probably been the larger debate: whether these patients are
entering dialysis with a high risk for atherosclerosis. Perhaps
that's why the first year of dialysis is so devastating and why
cardiovascular events account for a large proportion of terminal
events during the first year. Whether a large controlled trial
would be useful is unclear. Good evidence indicates that
hypertriglyceridemia itself does not correlate well as an inde-
pendent risk factor for atherosclerotic disease. On the other
hand, high triglyceride levels often are associated with low
HDL levels and abnormal HDL composition. These are the
abnormalities you would be trying to treat.
DR. MADIAS: Are the lipoprotein patterns you described
representative of children with renal disease, or do they apply
only to adults?
DR. APPEL: I know that for some populations like the
transplant population, the data seem pretty much the same.
Several studies have suggested that children with minimal-
change nephrotic syndrome might have a more favorable pat-
tern of hypercholesterolemia with a higher HDL than do adults.
That is, they would not be at risk for ischemic heart disease
later. On the other hand, one could argue that children with
minimal-change nephrotic syndrome are most likely to go into
long-term remission and therefore they are not at risk for the
chronic atherosclerotic complications of hyperlipidemia in any
case.
DR. HARRINGTON: One of your criteria for treating the
hypercholesterolemia of the nephrotic syndrome is that it be
sustained. How long is it safe to not treat a nephrotic patient
whose cholesterol is 350 mgldl or higher?
DR. APPEL: That's a very important question. Stewart Cam-
eron has suggested that patients should be nephrotic for 2 years
before you consider them to be at high risk [1]. I disagree. By
"sustained" I mean a pattern of nephrotic syndrome that is not
likely to go into remission either spontaneously or with therapy.
In a patient with minimal-change nephrotic syndrome, I would
not treat the hyperlipidemia, because one way or another we're
going to get the patient into remission. On the other hand, many
patients with membranous nephropathy, focal sclerosis, and
amyloidosis are more likely to remain nephrotic over the long
term; with those patients, I see no advantage in delaying
antihyperlipidemic therapy. As long as you know that the
patient will remain nephrotic for several months, I would begin
therapy. If the patient goes into remission, you can always stop
the treatment.
DR. MADIAS: In the experimental studies showing that a
decrease in dietary lipids protected renal function, were total
calories and amount of protein controlled in the diet?
DR. APPEL: The studies were controlled for the percentage of
protein in the diet. Animal data demonstrate that when one
lowers the lipid level and succeeds in decreasing albuminuria,
the percentage of glomerulosclerosis in these models lessens. In
all the (admittedly short-term) studies of lipid-lowering agents
in nephrotic patients, there's been no change in proteinuria or in
serum albumin or creatinine levels [63, 66—69]. Perhaps the
studies need to be longer. But we've used the HMG CoA
reductase inhibitors in nephrotic patients for several years, and
I haven't noticed any change in their proteinuna or their
albumin levels; in fact, some of them are developing progres-
sive renal failure. Thus, whether lowering lipids will have a
beneficial effect on the progression of renal disease in humans is
not clear.
DR. GEETHA NARAYAN (Division of Nephrology, St. Eliza-
beth's Hospital, Brighton, Massachusetts): Should we treat
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dialysis patients who have high triglycerides and low HDL?
What would you treat them with to raise the HDL?
Da. APPEL: The first approach is dietary therapy: low satu-
rated fat, low total fat (in terms of the percentage of intake), and
low cholesterol. All these factors have been shown to alter the
lipid abnormalities in uremic and dialyzed patients. In terms of
other approaches, low-dose clofibrate, which is not recom-
mended for this usage, has been successful in ameliorating
hypertriglyceridemia and altering the lipid pattern. This drug is
not recommended for use because it accumulates in patients
with renal failure and can cause toxicity. I don't know whether
another fibric acid derivative that is not excreted by the kidney
would be beneficial. I don't think these agents have been used
in dialyzed patients. Because we don't have good long-term
data on medications, I would suggest dietary manipulation and
other maneuvers that can raise HDL, such as exercise and the
avoidance of other risk factors, such as cessation of smoking
and control of hypertension.
DR. KLEMENS MEYER (Fellow, Division of Clinical Decision
Making, New England Medical Center): Just a point on gemfi-
brozil. The package insert lists renal failure as a contraindica-
tion to its use. But one European study found that gemfibrozil
lowers triglyceride levels and improves other parameters of
lipoprotein metabolism in patients with chronic renal insufli-
ciency [1651. The authors noted no adverse side effects.
DR. APPEL: Gemfibrozil has been used successfully in ne-
phrotic patients to gain improvement of the lipid profile, but I
have not used it myself on any dialysis patients, nor do I know
of anybody in New York who has used it.
Reprint requests to Dr. G. Appel, Director of Clinical Nephrology,
Columbia-Presbyterian Medical Center, New York, New York 10032-
3784, USA
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